Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Inogen
INGN
Inogen
Aging Global Population And At-Home Care Will Boost Market Demand
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
10 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$14.00
46.5% undervalued
intrinsic discount
16 Aug
US$7.49
Loading
1Y
-40.3%
7D
-1.2%
Author's Valuation
US$14.0
46.5% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$14.0
46.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-96m
503m
2014
2017
2020
2023
2025
2026
2028
Revenue US$503.0m
Earnings US$62.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
6.21%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.69%
Calculation
US$62.82m
Earnings '28
x
11.15x
PE Ratio '28
=
US$700.34m
Market Cap '28
US$700.34m
Market Cap '28
/
40.06m
No. shares '28
=
US$17.48
Share Price '28
US$17.48
Share Price '28
Discounted to 2025 @ 7.68% p.a.
=
US$14.00
Fair Value '25